Trial Profile

A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navitoclax (Primary) ; Venetoclax (Primary) ; Dexamethasone; Pegaspargase; Protein tyrosine kinase inhibitors; Vincristine
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Pharmacokinetics
Sponsors AbbVie

08 Dec 2020 Results (As of June 23, 2020; n=18) safety and efficacy of Venetoclax and Navitoclax in pediatric patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
08 Dec 2020 Status changed from active, no longer recruiting to completed.
21 Jun 2020 Results (n=46; as of 8 Nov 2019) presented at the 25th Congress of the European Haematology Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com